---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-001768"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:53:56.889251+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vir Bio: 88% HDV RNA undetectable at Week 96 in combo arm; cash ~$781M, runway to Q4 2027

## Summary
- Phase 2 SOLSTICE: 88% (21/24) of combo arm achieved undetectable HDV RNA at Week 96 vs 46% (11/24) monotherapy.
- No grade 3+ treatment-related AEs in combo arm; generally mild/moderate and transient.
- Cash, cash equivalents & investments ~$781M at Dec 31, 2025; runway extended into Q4 2027 via Norgine deal.
- ECLIPSE 1 Phase 3 topline data expected Q4 2026; ECLIPSE 2/3 top-line in Q1 2027.
- VIR-5500 Phase 1 data in prostate cancer to be presented at ASCO GU Feb 2026.

## SEC filing metadata
- accession: 0001628280-26-001768
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828026001768/0001628280-26-001768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828026001768/vir-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-001768
- JSON: https://secwatch.observer/filing/0001628280-26-001768.json
- Plain text: https://secwatch.observer/filing/0001628280-26-001768.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.